• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

Men rowing on a river
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 22nd October 2014

OHE at ISPOR Europe 1: Impact of NICE on Innovation and Value

ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. OHE’s Adrian Towse is current President of ISPOR and involved in several sessions. Important research on a range of topics will be presented by other members of…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

ISPOR’s 17th Annual European Congress is scheduled for 8-12 November 2014 in Amsterdam. OHE’s Adrian Towse is current President of ISPOR and involved in several sessions. Important research on a range of topics will be presented by other members of the OHE team, summarised briefly in this post. Please feel free to contact any of the OHE team members listed for additional information.

Impact of the National Institute of Care and Excellence (NICE)

The international effects of NICE

1.            Do NICE Decisions Affect Decisions in Other Countries? Karla Hernandez-Villafuerte (presenting), Martin Garau and Nancy Devlin [all OHE]

Based on 29 pairs of medicines or indications, this poster presents research that explored the extent of NICE’s impact. Information was collected from publicly available sources and an online survey. The countries included are Australia, Canada, Denmark, France, Italy, Korea, The Netherlands, New Zealand, Poland, Portugal, Spain, Bosnia-Herzegovina, Ecuador, Egypt and Ghana. (PHP86, 10 Nov, 15:30–19:30)

NICE’s effect on innovation and access to medical technologies

2.            Are the UK Systems of Innovation and Evaluation of Medical Devices Compatible? Amanda Chapman (OHE, presenting), Celia Taylor (University of Birmingham) and Alan Girling (University of Birmingham)

Innovation in medical devices and appropriate approaches to their evaluation are not the same as for pharmaceuticals. With this in mind, NICE created the Medical Technologies Evaluation Programme (MTEP) in 2009. This poster presents research that evaluates MTEP’s impact by comparing guidance output to date with NICE’s stated objectives in establishing the programme. (PHP239, 10 Nov, 15:30–19:30)

NICE’s impact on technology choices in health care systems

3.            Opportunity Costs of Implementing NICE Decisions in NHS Wales. Sarah Karlsberg Schaffer (OHE, presenting), Jon Sussex (OHE), Dyfrig Hughes (Bangor University) and Nancy Devlin (OHE)

This poster examines how Local Health Boards (LHBs) in Wales adjust spending to meet the statutory requirement of providing access to technologies recommended by NICE within three months after NICE publishes a Technology Appraisal. Based on interviews with medical and/or finance directors of the seven Wales LHBs, the study covers the period from October 2010 through March 2013. (PHP109, 10 Nov, 15:30–19:30)

For a recent version of the study, click here.

Methods: understanding NICE’s approaches to assessment

4.            Value-based Assessment for NICE: How to Do the Calculations. Discussion Leaders: Jeanette Kusel (Costello Medical Consulting Ltd), Meindert Boysen (NICE), Koonal K. Shah (OHE) and Anthony J Hatswell (BresMed)

This workshop originally intended to explain calculations for estimating ‘absolute QALY shortfall’ and ‘proportional QALY shortfall’, two possible measures of burden of illness in NICE’s value-based assessment proposals. NICE since has put this approach on hold. The workshop will focus on the research that provided the arguments for the proposals. (W5, 10 Nov, 16:45–17:45)

Effect on patients’ access to new technologies

5.            Measuring Extent of Access for NICE Health Technology Assessment Decisions: Trends from 2008 to 2013. Phill O’Neill (presenting) and Nancy Devlin [both OHE]

Using 201 NICE decisions between 2008 and 2013, this research analyses NICE’s recommendations for partial use of a product (“optimising” or “restricting” its use within the licensed indication) setting out the proportion of potential patients for which NICE actually recommended access. (PHP 220, 10 Nov, 15:30–19:30)

  • Health Technology Assessment…
  • Economics of Innovation
  • Innovation

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!